Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 35Active not recruiting 14Terminated 9Recruiting 6Withdrawn 4Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6CNS 4Head & Neck 3Tumor-Agnostic 2Thoracic 2Genitourinary 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1Breast 1

Conditions

Rhabdomyosarcoma 1

Interventions

Doxorubicin 5Cyclophosphamide 4Vincristine 3Temozolomide 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Injections 3polatuzumab vedotin 2liposomal doxorubicin 2glofitamab 2envafolimab 2anlotinib 2X-Rays 2Radiotherapy 2Prednisone 2Nivolumab 2Imatinib Mesylate 2Biopsy 2AZD 6244 2toripalimab 1surufatinib 1relmacabtagene autoleucel 1regorafenib 1pemigatinib 1pazopanib 1obinutuzumab 1montelukast 1irinotecan sucrosofate 1fludarabine 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Radiation × Sarcoma × Clear all
NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡